	US 12,441,816 B2
	Heterodimeric Fc for making fusion proteins and bispecific antibodies
Zhi Liu, Shoreline, WA (US); Victor Hermand, Lynnwood, WA (US); Hua Liu, Shoreline, WA (US); and Wei Yan, Sammamish, WA (US)
Assigned to QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION, Bothell, WA (US)
Filed by QILU PUGET SOUND BIOTHERAPEUTICS CORPORATION, Bothel, WA (US)
Filed on Sep. 21, 2022, as Appl. No. 17/933,954.
Claims priority of provisional application 63/246,573, filed on Sep. 21, 2021.
Prior Publication US 2023/0116446 A1, Apr. 13, 2023
Int. Cl. C07K 16/46 (2006.01); C07K 16/28 (2006.01); C12N 15/86 (2006.01)

CPC C07K 16/462 (2013.01) [C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C12N 15/86 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/53 (2013.01); C07K 2317/565 (2013.01); C07K 2319/00 (2013.01)]

46 Claims

1. A variant-Fc-region comprising a set of amino acid substitutions compared to native human IgG1, IgG2, or IgG4, selected from: a first variant-Fc-region comprising S364D, K370D, N390D, K392G and S400D; or a second variant-Fc-region comprising S364K, N390P and S400K, according to EU numbering.